

Mary Caitlin King Bs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4012379/publications.pdf>

Version: 2024-02-01

27
papers

159
citations

1163117

8
h-index

1199594

12
g-index

28
all docs

28
docs citations

28
times ranked

165
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 473-481.	1.5	23
2	Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1598-1606.	1.0	15
3	Overcoming Barriers in the Implementation of Programs for Breast and Cervical Cancers in Cali, Colombia: A Pilot Model. <i>Journal of Global Oncology</i> , 2019, 5, 1-9.	0.5	15
4	Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). <i>Annals of Surgical Oncology</i> , 2020, 27, 179-187.	1.5	13
5	Impact of Mucin Cellularity and Distribution on Survival in Newly Diagnosed Patients with Low-Grade Appendiceal Mucinous Neoplasm Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 4908-4917.	1.5	12
6	Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix. <i>Annals of Surgical Oncology</i> , 2022, 29, 3390-3401.	1.5	12
7	Defining "Complete Cytoreduction" After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis. <i>Annals of Surgical Oncology</i> , 2020, 27, 5026-5036.	1.5	11
8	Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience. <i>Journal of Surgical Oncology</i> , 2021, 123, 1030-1044.	1.7	11
9	Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent. <i>International Journal of Surgical Oncology</i> , 2018, 2018, 1-9.	0.6	9
10	Selection and Characteristics of Patients with Peritoneal Dissemination from Appendiceal Cancer with Exceptional/Poor Survival After CRS/HIPEC. <i>Annals of Surgical Oncology</i> , 2019, 26, 2268-2275.	1.5	7
11	Pelvic Anastomosis Without Protective Ileostomy is Safe in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 4931-4940.	1.5	7
12	Cytoreductive Surgery with Hyperthermic Intrathoracic Chemotherapy for Patients with Intrapleural Dissemination of Peritoneal Surface Malignancies. <i>Annals of Surgical Oncology</i> , 2021, 28, 9126-9135.	1.5	7
13	Germline and somatic genetic alterations in two first-degree relatives with appendiceal low-grade mucinous carcinoma peritonei. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3168-3177.	0.5	3
14	Mobile Applications: Breaking Barriers to Early Breast and Cervical Cancer Detection in Underserved Communities. <i>JCO Oncology Practice</i> , 2021, 17, e323-e335.	2.9	3
15	Systemic Chemotherapy for High-Grade Mucinous Appendiceal Cancer with Peritoneal Spread After Unsuccessful CRS/HIPEC. <i>Annals of Surgical Oncology</i> , 2022, 29, 6581-6589.	1.5	3
16	Pre- and post-operative antibiotics in conjunction with cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) should be considered for pseudomyxoma peritonei (PMP) treatment. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1723-1726.	1.0	2
17	ASO Visual Abstract: Cytoreductive Surgery with Hyperthermic Intrathoracic Chemotherapy for Patients With Intrapleural Dissemination of Peritoneal Surface Malignancies. <i>Annals of Surgical Oncology</i> , 2021, 28, 519-519.	1.5	2
18	Management of Low-Grade Appendiceal Mucinous Neoplasm with Extensive Peritoneal Spread Diagnosed during Pregnancy: Two Case Reports and Literature Review. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-9.	0.3	1

#	ARTICLE	IF	CITATIONS
19	ASO Visual Abstract: Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	1
20	The Role of Microorganisms in Appendiceal Pseudomyxoma Peritonei: A Review. <i>Current Oncology</i> , 2022, 29, 3576-3584.	2.2	1
21	ASO Author Reflections: CRS/HIPEC Cannot be Done—Now what? Systemic Chemotherapy in Mucinous Appendiceal Cancer. <i>Annals of Surgical Oncology</i> , 0, , .	1.5	1
22	ASO Author Reflections: Not All Low-Grade Appendiceal Mucinous Neoplasm Mucin is Created Equal. <i>Annals of Surgical Oncology</i> , 2020, 27, 4918-4919.	1.5	0
23	ASO Author Reflections: Time to Change: Redefining “Complete Cytoreduction” in Appendiceal Carcinomatosis. <i>Annals of Surgical Oncology</i> , 2020, 27, 5037-5038.	1.5	0
24	ASO Author Reflections: Pleural Spread of Peritoneal Malignancies: When Heated Chemoperfusion Can Save the Day. <i>Annals of Surgical Oncology</i> , 2021, 28, 9136-9137.	1.5	0
25	ASO Author Reflections: Is CRS/HIPEC an Indication to Divert Rectal Anastomosis?. <i>Annals of Surgical Oncology</i> , 2020, 27, 4941-4942.	1.5	0
26	ASO Author Reflections: If at First You Don’t Succeed, Try, Try Again: Iterative CRS/HIPEC for Recurrent Mucinous Appendix Cancer. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
27	Reply to: Letter to editor “Rare, but severe: Delayed Genitoscrotal necrosis after HIPEC with Mitomycin-3. <i>European Journal of Surgical Oncology</i> , 2022, 48, 705.	1.0	0